Admedus (ASX:AHZ) said today it won a supply contract with the new Royal Adelaide Hospital for the installation of the Arcomed chroma infusion pump systems.
Swiss infusion technology company Arcomed’s Chroma infusion pumps are designed to provide a whole-of-hospital system and include LCD touch screens, drug error reduction systems and on-screen color coding of medication, Admedus said.
“We are encouraged by the uptake of arcomed Chroma Infusion pump systems within Australia which confirms both the quality and value to the health care system of the product range. As outlined in the recent quarterly report, the Admedus team remains focused on providing hospital-wide infusion solutions across the Australian and New Zealand healthcare systems,” Admedus chair Wayne Paterson said in a press release.
The supply tender includes ongoing technical and clinical support as well as consumable products for the systems over the next 5 years.
“Arcomed is proud to partner with the new Royal Adelaide Hospital and Admedus to bring the latest innovations in infusion technology to the State’s flagship hospital. The decision from the new RAH confirms that arcomed is delivering the infusion technology hospitals today need to help them achieve their goals of patient safety, convenience and cost effectiveness,” Arcomed global biz director Beat Rechsteiner said in a prepared statement.
Admedus has one of the largest infusion product ranges on market in Australia and New Zealand, demonstrating the Company’s ability to provide complex infusion solutions across hospitals and healthcare services groups.
Admedus shares rose as much as 18.5% to 28¢ (AU 38¢), joining the top percentage gains on the ASX all ordinaries index upon release of the news.
In January, Admedus said it inked an exclusive distribution agreement with Coroneo to sell its Extra aortic annuloplasty ring ing and other heart valve surgery instruments in Germany and the U.K.
Canada-based Coroneo’s Extra aortic ring is designed to repair aortic valves by supporting dystrophic aortic tissue and a downsized dilated valve annulus to restore proper cusp contact.
Admedus said the Extra aortic ring is complimentary to the company’s own CardioCel bio-scaffolds, which are regenerative tissue patches designed for cardiac and vascular repairs and reconstructions and promote autologous growth.
Sales of the Extra aortic ring will operate through Admedus’ existing sales and marketing infrastructure.